Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipecac’s status

This article was originally published in The Tan Sheet

Executive Summary

Recommendations by FDA's Nonprescription Drugs Advisory Committee meeting June 12 to discontinue Ipecac's OTC status "do not adequately represent the perspective of many practicing medical toxicologists," Richard Dart, MD/PhD, says in July 22 comments filed with the agency (1"The Tan Sheet" June 16, 2003, p. 3). Ipecac is useful in cases of iron and acetaminophen ingestion and for households in rural areas, the Rocky Mountain Poison Center Director argues. Therefore, Dart requests FDA wait until the tentative final monograph for OTC Poison Treatment Drug Products is "adopted before making its decision on the fate of syrup of Ipecac"...
Advertisement

Related Content

Ipecac OTC Status Withdrawal Advised By NDAC Majority
Ipecac OTC Status Withdrawal Advised By NDAC Majority

Topics

Advertisement
UsernamePublicRestriction

Register

PS095875

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel